Furosemide Injection shortage (US): status and presentations
Shortage United States · first listed 7 April 2020 · updated 15 October 2026
| Dosage form | Injection |
|---|---|
| Therapy area | Cardiovascular |
| Presentations | 11 unavailable, 0 limited, 16 available |
| Source | US FDA Drug Shortage Database (openFDA), checked 19 October 2026 |
Presentations affected
- Furosemide, Injection, 10 mg/1 mL — Unavailable
- Furosemide, Injection, 100 mg/ 10mL (10 mg/1 mL) — Unavailable
- Furosemide, Injection, 20 mg/2 mL — Unavailable
- Furosemide, Injection, 20 mg/2 mL (10 mg/1 mL) — Unavailable
- Furosemide, Injection, 40 mg/4 mL (10 mg/1 mL) — Unavailable
- Furosemide, Injection, 10 mg/mL, 2 mL — Available
- Furosemide, Injection, 100 mg/10 mL — Available
- Furosemide, Injection, 40 mg/4 mL — Available
Strengths and packs as listed by the regulator. Manufacturer names and product codes are not shown.
What buyers can do
- Check whether other registered presentations or strengths can be used, and ask your wholesaler about allocation.
- For hospital and tender supply, look for manufacturers that already hold an approval in your market and can increase output.
- In a critical shortage, the FDA can allow temporary importation of a version approved in a well-regulated market. That decision is made by the FDA, case by case.
- Qualify any new source as carefully as at any other time: GMP certificate, registration status and a certificate of analysis for each batch.
See the product page for Furosemide Injection on PharmaTradz.
More: where licensed suppliers can step in during US shortages.
Need Furosemide Injection?
Send a request with your market, strength and quantity. We match licensed buyers with qualified suppliers.
Request a quote I can supply thisFollow this shortage
We email you when its status changes. Confirm first; unsubscribe any time.
Related shortages
For information only. Shortage status changes often; confirm with the regulator before making decisions. Brand names, where shown, are trademarks of their owners.
